Need professional-grade analysis? Visit stockanalysis.com
$3.21B
10.00
704
N/A
Price Chart
Risk-Adjusted Performance
Also Listed On
Galapagos NV (GLPGF) Price Performance
Galapagos NV (GLPGF) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $33.27.
Over the past year, GLPGF has traded between a low of $22.39 and a high of $34.00. The stock has gained 44.6% over this period. It is currently 48.6% above its 52-week low.
Galapagos NV has a market capitalization of $3.21B, with a price-to-earnings ratio of 10.00.
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $1.11B
- EBITDA
- $560.05M
- Profit Margin
- 28.85%
- EPS (TTM)
- -7.78
- Book Value
- 56.30
Technical Indicators
- 52 Week High
- $34.00
- 52 Week Low
- $22.39
- 50 Day MA
- $32.79
- 200 Day MA
- $31.54
- Beta
- 0.10
Valuation
- Trailing P/E
- 10.00
- Forward P/E
- 322.58
- Price/Sales
- 2.89
- Price/Book
- 0.78
- Enterprise Value
- $-1,408,409,780